InvestorsHub Logo
Followers 3
Posts 235
Boards Moderated 0
Alias Born 08/22/2016

Re: None

Tuesday, 10/17/2017 8:45:02 AM

Tuesday, October 17, 2017 8:45:02 AM

Post# of 504
8K today: On October 13, 2017, Infinity Pharmaceuticals, Inc. (“Infinity”) received a $6,000,000 cash payment from Verastem, Inc. (“Verastem”) under the Amended and Restated License Agreement effective October 29, 2016 between Infinity and Verastem. The payment was made following the determination that the Phase 3 DUO clinical study evaluating the efficacy and safety of duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma met certain pre-specified criteria at completion.